Fresenius Kabi, a provider of infusion therapy and clinical nutrition is to acquire Fenwal, a specialist in separation technologies for blood and cell collection and therapy. Fenwal is owned by TPG and is based in Lake Zurich, Illinois.
Fresenius Kabi, a leading provider of infusion therapy and clinical nutrition, and Fenwal Inc. a global leader specializing in separation technologies for blood and cell collection and therapy, announced today a definitive agreement for Fresenius Kabi to acquire Fenwal.
The acquisition brings together two leaders in health care with complementary products, strategies and geographic presence. Working together, the companies will bring their customers a wider array of products and services, while continuing to increase their pace of product development and geographic expansion.
The acquisition, which is subject to customary conditions, is expected to be completed by the end of the year. Financial terms were not disclosed.
“Fenwal has built a leadership position centered on separation technology used to collect and process blood and to treat disease,” said Rainer Baule, chairman and chief executive officer of Fresenius Kabi. “Like Fresenius Kabi, Fenwal has a unique and long history serving health care, productive relationships with customers and researchers, and a rich pipeline of new products that are essential to patients and those who care for them.”
“The products, services, technologies and cultures of both companies fit extremely well together,” said Ron Labrum, Fenwal president and chief executive officer. “We are committed to assuring a smooth integration with Fresenius Kabi and to bringing our customers even more value as a result of this unique combination.”
Fenwal has unique expertise in developing and applying technologies for blood collection and separation. Its products are used worldwide to support and protect the blood supply, as well as in the delivery of blood-transfusion therapies.
For more than 60 years, blood centers, plasma collectors and hospitals have used Fenwal technology to collect blood and blood components. With the recent growth and potential of cell therapies for cancer, Alzheimer’s disease and other conditions, Fenwal has also become a partner of choice for researchers and established biotech and pharmaceutical companies.
Fenwal, Inc. is a global medical technology company focused on improving transfusion medicine through unique expertise in blood separation, collection, filtration, storage and transfusion. The company offers a broad range of products and services for the automated and manual collection of blood and blood components. Fenwal products and advanced collection and separation technologies are used to help treat patients on six continents. Fenwal, Inc. is based in Lake Zurich, Illinois.
About Fresenius Kabi
Fresenius Kabi is focused on the therapy and care of critically and chronically ill patients inside and outside the hospital. Its portfolio comprises a wide range of IV drugs, infusion therapies, clinical nutrition products as well as the related medical devices. For transfusion technology, Fresenius Kabi offers a range of products used by blood banks and blood donation units to produce blood products. With a corporate philosophy of “caring for life,” the company’s goal is to improve the patient’s quality of life. Fresenius Kabi AG is a 100 percent subsidiary of the health care group Fresenius SE & Co. KGaA.
SOURCE: Fenwal, Inc.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.